ISCNF - Isracann to acquire natural health medicine developer

Isracann Biosciences (OTCPK:ISCNF) to acquire Praesidio Health of Canada. The appointment of Mr. Phil Floucault to the position of company’s CEO in late October of 2021, allowed for a period of investigation, reflection and ultimately offered an opportunity for Mr. Floucault to examine parallel complementary business opportunities within his extensive business network.  Company also announces it has signed an agreement with Promethean Marketing to provide digital marketing services. Terms are for the offering of services for one month beginning February 23, 2022. As consideration for the contract, the company has made payments totaling $65,000.

For further details see:

Isracann to acquire natural health medicine developer